FLT3 and acute myeloid leukemia: The combinational therapy was also tested in the AML cell lines OCI-AML3 (wild type TP53, wild type FLT3) and HL60 (deleted TP53), and in normal peripheral blood lymphocytes, demonstrating decreased sensitivity in cells with wild type TP53 and wild type FLT3 compared to cells with wild type TP53 and mutated FLT3, and no effect in cells with deleted TP53 or in normal cells in Annexin-PI viability assay (Figure 5C).